Stability in eosinophil categorisation during subsequent severe exacerbations of COPD

被引:13
作者
Citgez, Emanuel [1 ,2 ]
van der Palen, Job [2 ,3 ]
van der Valk, Paul [1 ]
Kerstjens, Huib A. M. [4 ,5 ]
Brusse-Keizer, Marjolein [3 ]
机构
[1] Med Spectrum Twente, Dept Pulm Med, Enschede, Netherlands
[2] Univ Twente, Dept Res Methodol Measurement & Data Anal, Enschede, Netherlands
[3] Med Spectrum Twente, Med Sch Twente, Enschede, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med, Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, Groningen, Netherlands
关键词
COPD exacerbations; eosinophil biology; pulmonary eosinophilia; COPD epidemiology; OBSTRUCTIVE PULMONARY-DISEASE; BLOOD EOSINOPHILS; PREDNISOLONE; PREDICTORS; BIOMARKER; ASTHMA;
D O I
10.1136/bmjresp-2021-000960
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background The blood eosinophil count has been shown to be a promising biomarker for establishing personalised treatment strategies to reduce corticosteroid use, either inhaled or systemic, in chronic obstructive pulmonary disease (COPD). Eosinophil levels seem relatively stable over time in stable state, but little is known whether this is also true in subsequent severe acute exacerbations of COPD (AECOPD). Aims and objectives To determine the stability in eosinophil categorisation between two subsequent severe AECOPDs employing frequently used cut-off levels. Methods During two subsequent severe AECOPDs, blood eosinophil counts were determined at admission to the hospital in 237 patients in the Cohort of Mortality and Inflammation in COPD Study. The following four cut-off levels were analysed: absolute counts of eosinophils >= 0.2 x 10(9)/L (200 cells/mu L) and >= 0.3 x 10(9)/L (300 cells/mu L) and relative eosinophil percentage of >= 2% and >= 3% of total leucocyte count. Categorisations were considered stable if during the second AECOPD their blood eosinophil status led to the same classification: eosinophilic or not. Results Depending on the used cut-off, the overall stability in eosinophil categorisation varied between 70% and 85% during two subsequent AECOPDs. From patients who were eosinophilic at the first AECOPD, 34%-45% remained eosinophilic at the subsequent AECOPD, while 9%-21% of patients being non-eosinophilic at the first AECOPD became eosinophilic at the subsequent AECOPD. Conclusions The eosinophil variability leads to category changes in subsequent AECOPDs, which limits the eosinophil categorisation stability. Therefore, measurement of eosinophils at each new exacerbation seems warranted.
引用
收藏
页数:7
相关论文
共 22 条
  • [1] Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
    Bafadhel, Mona
    Peterson, Stefan
    De Blas, Miguel A.
    Calverley, Peter M.
    Rennard, Stephen I.
    Richter, Kai
    Fageras, Malin
    [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (02) : 117 - 126
  • [2] Eosinophils in COPD: just another biomarker?
    Bafadhel, Mona
    Pavord, Ian D.
    Russell, Richard E. K.
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (09) : 747 - 759
  • [3] Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis
    Bafadhel, Mona
    Davies, Lisa
    Calverley, Peter M. A.
    Aaron, Shawn D.
    Brightling, Christopher E.
    Pavord, Ian D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (03) : 789 - 791
  • [4] Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial
    Bafadhel, Mona
    McKenna, Susan
    Terry, Sarah
    Mistry, Vijay
    Pancholi, Mitesh
    Venge, Per
    Lomas, David A.
    Barer, Michael R.
    Johnston, Sebastian L.
    Pavord, Ian D.
    Brightling, Christopher E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (01) : 48 - 55
  • [5] Acute Exacerbations of Chronic Obstructive Pulmonary Disease Identification of Biologic Clusters and Their Biomarkers
    Bafadhel, Mona
    McKenna, Susan
    Terry, Sarah
    Mistry, Vijay
    Reid, Carlene
    Haldar, Pranabashis
    McCormick, Margaret
    Haldar, Koirobi
    Kebadze, Tatiana
    Duvoix, Annelyse
    Lindblad, Kerstin
    Patel, Hemu
    Rugman, Paul
    Dodson, Paul
    Jenkins, Martin
    Saunders, Michael
    Newbold, Paul
    Green, Ruth H.
    Venge, Per
    Lomas, David A.
    Barer, Michael R.
    Johnston, Sebastian L.
    Pavord, Ian D.
    Brightling, Christopher E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (06) : 662 - 671
  • [6] A sputum gene expression signature predicts oral corticosteroid response in asthma
    Berthon, Bronwyn S.
    Gibson, Peter G.
    Wood, Lisa G.
    MacDonald-Wicks, Lesley K.
    Baines, Katherine J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (06)
  • [7] Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
    Brightling, CE
    Monteiro, W
    Ward, R
    Parker, D
    Morgan, MDL
    Wardlaw, AJ
    Pavord, ID
    [J]. LANCET, 2000, 356 (9240) : 1480 - 1485
  • [8] Comparing the 2007 and 2011 GOLD Classifications as Predictors of all-Cause Mortality and Morbidity in COPD
    Brusse-Keizer, M.
    Klatte, M.
    Zuur-Telgen, M.
    Koehorst-ter Huurne, K.
    van der Palen, J.
    VanderValk, P.
    [J]. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 14 (01) : 7 - 14
  • [9] Blood eosinophil levels as a biomarker in COPD
    Brusselle, Guy
    Pavord, Ian D.
    Landis, Sarah
    Pascoe, Steven
    Lettis, Sally
    Morjaria, Nikhil
    Barnes, Neil
    Hilton, Emma
    [J]. RESPIRATORY MEDICINE, 2018, 138 : 21 - 31
  • [10] Asthma-COPD Overlap
    Christenson, Stephanie A.
    Steiling, Katrina
    van den Berge, Maarten
    Hijazi, Kahkeshan
    Hiemstra, Pieter S.
    Postma, Dirkje S.
    Lenburg, Marc E.
    Spira, Avrum
    Woodruff, Prescott G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (07) : 758 - 766